AMP German Cannabis Group announces AGM results and appointment of new CFO

ERFURT and BERLIN, Germany, June 29th, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (FSE: C4T, ISIN: CA00176G1028) (CSE: XCX) held its annual general meeting of shareholders (AGM) earlier today. The shareholders approved all resolutions put before them, namely: 

• Re-electing Dr. Stefan Feuerstein and Messrs. Alex Blodgett, Claudio Morandi and Kenneth MacLeod as directors of the Company; 

• Re-appointed Dale Matheson Carr-Hilton Labonte LLP, Chartered Accountants, as the Company’s auditor for the ensuing year and authorizing the directors to set the auditor’s remuneration. 

After the AGM, AMP published a pre-recorded online question and answer session with Dr. Stefan Feuerstein, President and Director of AMP. Watch video on the following link: 

AMP also announces the appointment of Mr. Nick Furber as Chief Financial Officer (CFO) and as a new member to its board of directors. Mr. Furber will oversee financial aspects of the company, including financial planning and analysis, accounting, and financial reporting, managing tax, treasury, internal audit, and investor relations. 

Mr. Furber has over two decades of experience in financial reporting, management, corporate finance, and business development in multiple industries including medical, mining, and financial services and has been the CFO for companies listed in Canada, Germany and the United States. Previously, Mr. Furber worked for PricewaterhouseCoopers in the United Kingdom and Canada, primarily in their Corporate Finance and Transaction Services groups. Mr. Furber is a Chartered Accountant (ICAEW) and Chartered Financial Analyst (CFA) charter holder. 

Mr. Alex Blodgett, CEO & Director, commented, “We would like to thank Ms. Christine McPhie for her contribution as the Company’s CFO and her help in ensuring an orderly transition. We wish Ms. McPhie all the best in her retirement.” 

About AMP German Cannabis Group Inc. 

AMP German Cannabis Group is licensed to import European Union – Good Manufacturing Practice (EU-GMP) medical cannabis and sell to pharmaceutical distributers or pharmacists directly, the only point-of-sale for medical cannabis to German patients. 

AMP has entered into a non-exclusive distribution agreement for medical cannabis with a leading distributor of pharmaceuticals products to more than 13,000 pharmacies throughout Germany for monthly shipments starting in the second half of 2020. For more information, please visit: 


Mr. Alex Blodgett, CEO and Director 

Telephone: +236-833-1602 


AMP social media links: 

• Twitter: 



AMPMedia Kit:

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE)accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statementsthat arebased on theCompany’s expectations,estimates and projectionsregarding its business and the economicenvironmentin which it operates,including with respectto its business plans and milestones and the timing thereof. Although the Companybelieves the expectations expressed in such forward-looking statements are based on reasonableassumptions,such statements are not guarantees offuture performance andinvolve risks and uncertaintiesthat are difficult to control or predict. Therefore, actual outcomesand resultsmaydiffer materially fromthose expressed in these forward-looking statements and readers should not place undue reliance on suchstatements.These forward-looking statements speak only as of the date on which they are made, and theCompany undertakes no obligation to update them publicly to reflect new information or the occurrence offuture events or circumstances unless otherwise required to do so by law.

SOURCE AMP German Cannabis Group Inc.